List of Excipients in Branded Drug IRON DEXTRAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	IRON DEXTRAN	iron dextran	51662-1441	SODIUM HYDROXIDE

Iron Dextran Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Iron dextran is an established intravenous and intramuscular iron replacement product with limited potential for conventional composition-of-matter exclusivity. The strongest commercial opportunities are in safer excipient systems, ready-to-use presentations, low-volume administration, supply reliability, and differentiated products for patients who cannot tolerate or access newer intravenous iron complexes.

The core formulation challenge is preserving the iron-dextran colloidal complex while controlling hypersensitivity risk, oxidation, particulate formation, viscosity, osmolality, container interaction, and long-term stability. The most defensible product strategies are likely to rely on formulation, device, manufacturing, and method-of-use claims rather than broad excipient substitution alone.

What is the current FDA status of iron dextran?

Iron dextran is an FDA-approved parenteral iron product used for iron-deficiency anemia when oral iron is ineffective, contraindicated, or insufficient. The principal marketed reference product is INFeD, iron dextran injection, supplied at 50 mg elemental iron per mL.[1]

Key FDA product data

Attribute	Iron dextran
Active ingredient	Iron dextran complex
Elemental iron concentration	50 mg/mL
Routes	Intravenous and intramuscular, depending on product labeling
Dosage forms	Sterile injectable solution
Primary use	Iron-deficiency anemia
FDA pathway	New Drug Application and generic or abbreviated pathways, depending on sponsor
Reference product	INFeD
Typical presentation	Single-dose or multiple-dose vial presentations
Key clinical risk	Serious hypersensitivity, including anaphylactic-type reactions
Administration constraint	Test dosing and observation requirements may apply under labeling

The FDA labeling describes iron dextran as a colloidal complex rather than a simple dissolved iron salt. The dextran component controls iron release and contributes to the product's pharmacokinetic and immunologic profile.[1]

Iron dextran is commercially distinct from ferric carboxymaltose, ferumoxytol, iron sucrose, ferric derisomaltose, and sodium ferric gluconate. Those products use different carbohydrate or ligand systems and have different dosing, safety, administration, and intellectual-property profiles.

What excipients are used in iron dextran injection?

The conventional excipient system is intentionally simple. FDA labeling for INFeD identifies sodium chloride and water for injection as inactive ingredients, with pH adjustment as necessary.[1]

Baseline excipient architecture

Formulation component	Function	Commercial and regulatory relevance
Iron dextran complex	Active iron delivery system	Determines iron release, tolerability, and complex stability
Sodium chloride	Tonicity adjustment	Low regulatory novelty; useful for isotonicity control
Water for injection	Vehicle	Standard parenteral solvent
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls colloidal stability and degradation
Container closure system	Product protection	Can affect adsorption, extractables, leachables, and shelf life

A minimal excipient profile reduces compatibility and immunogenicity concerns. It also limits opportunities to obtain broad formulation patents. Commercial differentiation therefore depends more heavily on process control, presentation, administration method, and evidence supporting a clinically useful advantage.

Potential excipients such as polysorbates, phosphate buffers, citrate, amino acids, polyols, antioxidants, chelators, or surfactants require careful justification. They may alter particle size, iron release, dextran conformation, protein interaction, osmolality, viscosity, or hypersensitivity risk.

How should an excipient strategy for iron dextran be designed?

The preferred strategy is to begin with the iron-dextran complex and make the smallest excipient intervention needed to solve a defined commercial problem.

1. Optimize pH without destabilizing the complex

pH is likely to be the most important formulation variable. A useful development program should map:

• iron release across the intended pH range;
• particle-size distribution;
• visible and subvisible particles;
• precipitation or flocculation;
• viscosity;
• free iron;
• dextran molecular-weight distribution;
• degradation under thermal and light stress;
• compatibility with infusion systems and syringes.

A narrow pH specification can support batch consistency and a potential process-control claim. A broad pH adjustment alone is unlikely to create meaningful patent differentiation.

2. Control tonicity without unnecessary ionic complexity

Sodium chloride is a conventional choice. Alternative tonicity agents may include dextrose, glycerol, sorbitol, or other parenterally acceptable polyols. Each alternative creates potential benefits and risks:

Excipient option	Potential benefit	Principal risk
Sodium chloride	Familiar, inexpensive, established	Ionic-strength effects on colloidal stability
Dextrose	Tonicity adjustment and compatibility with certain infusion settings	Chemical stability and glycation-related concerns
Glycerol	Reduced ionic burden	Viscosity and injection tolerability
Sorbitol	Tonicity adjustment	Oxidation, osmolality, and impurity control
Amino acid buffer	pH control or stabilization	Complexation and biological compatibility
Citrate or phosphate	Buffer capacity	Iron binding, precipitation, or altered release
Polysorbate	Interfacial protection	Oxidation, peroxide formation, and injection safety
EDTA or other chelator	Control of trace-metal catalysis	Altered iron availability and regulatory complexity

The most commercially realistic alternatives are low-level nonionic tonicity agents or carefully selected buffer systems. Strong chelators and surfactants are less attractive because they can interfere with iron chemistry and introduce new impurity specifications.

3. Evaluate antioxidant strategies cautiously

Iron can catalyze oxidative reactions. An antioxidant may improve stability in some systems, but iron-binding antioxidants can change the active complex. Potential candidates must be tested for:

• free iron generation;
• peroxide formation;
• color change;
• dextran chain scission;
• container interaction;
• infusion-line compatibility;
• hypersensitivity potential.

A successful antioxidant system could support a differentiated shelf-life or storage claim. It would not automatically support substitution without comparative clinical and regulatory work.

4. Avoid preservatives unless the presentation requires them

Preservatives may support a multidose vial, but they increase the burden for a product administered intravenously or intramuscularly. Benzyl alcohol, phenol, parabens, and related preservatives raise concerns involving neonatal exposure, local tolerability, hypersensitivity, and compatibility.

A preservative-free single-dose vial or ready-to-use syringe is generally a stronger commercial direction than a preserved multidose product. It aligns with hospital safety practices and reduces preparation steps.

What formulation patents could protect iron dextran products?

The most protectable opportunities are narrow, technically defined, and linked to measurable performance.

Potential patent claim categories

Claim category	Example subject matter	Relative commercial value
Excipient composition	Iron dextran with a defined buffer, tonicity agent, or stabilizer	Moderate if linked to unexpected stability or safety
pH range	A narrow pH window producing lower free iron or fewer particles	Moderate
Particle-size control	Defined colloidal size distribution and iron-release profile	High if reproducible and clinically relevant
Process controls	Defined mixing, temperature, addition rate, or purification sequence	High for manufacturing barriers
Container closure	Low-sorption syringe, vial, stopper, or polymer system	Moderate
Ready-to-use presentation	Pre-diluted or fixed-dose syringe or infusion container	Moderate to high
Administration method	Faster infusion with a defined formulation and monitoring protocol	High if clinically supported
Stability	Long-term storage at controlled or room temperature	Commercially meaningful
Combination therapy	Iron dextran with a defined anemia-treatment regimen	Usually method-of-use protection
Device integration	Autoinjector, infusion cassette, or dose-confirming system	Potentially valuable, but route limitations matter

A broad claim covering "iron dextran plus a pharmaceutically acceptable excipient" would face significant validity and obviousness pressure. A stronger application would link the excipient to a specific technical result, such as reduced free iron, improved particle stability, lower injection-site reaction, reduced adsorption, or increased shelf life.

Manufacturing patents may be stronger than excipient patents

Iron-dextran manufacturing can involve complex control over dextran source material, molecular-weight distribution, iron loading, oxidation state, reaction conditions, purification, and sterilization. A process that consistently produces a defined complex with lower free iron or a narrower release profile may create a more durable barrier than a conventional excipient combination.

Manufacturing claims can also be difficult for competitors to design around when the claimed quality attributes are necessary to meet the product specification.

When does iron dextran lose exclusivity?

The original exclusivity period for iron dextran has expired. INFeD was approved decades ago, and the product is now commercially positioned as an established injectable rather than a recently launched innovative medicine.[1]

Patent and regulatory exclusivity

Protection type	Current strategic relevance
Original composition patent	Expired or commercially obsolete
Original FDA exclusivity	Expired
Orange Book listing	Must be checked against the current FDA Orange Book for the relevant reference product and listing status
Formulation patents	Potentially available only for new, non-obvious compositions
Method-of-use patents	Possible for defined dosing or patient populations
Manufacturing patents	Potentially important for complex quality attributes
Pediatric exclusivity	No general current basis assumed
Orphan exclusivity	Not inherent to iron dextran

Because iron dextran is an old small-molecule complex product, generic entry risk is primarily regulatory and commercial rather than based on a surviving foundational patent. A sponsor seeking new protection would need to create a technically differentiated product with supporting stability, pharmacology, safety, and clinical evidence.

What is the Orange Book and Paragraph IV risk for iron dextran?

The Orange Book identifies approved drug products and relevant patent or exclusivity information submitted to FDA.[2] A Paragraph IV challenge would be relevant only if an applicant seeks approval of a product referencing a listed drug with an unexpired patent.

For an iron dextran developer, the practical assessment should focus on:

1. whether the reference product has active listed patents;
2. whether those patents cover formulation, method of use, or presentation;
3. whether a generic applicant can use a different excipient system;
4. whether the proposed label requires a patented method;
5. whether the product qualifies for an abbreviated pathway;
6. whether FDA regards the proposed product as therapeutically equivalent.

A Paragraph IV strategy is more likely to target a newly developed iron-dextran formulation than the legacy active ingredient itself. A new sponsor should expect patent scrutiny around particle size, complex characteristics, excipient ratios, stability, and administration protocols.

What generic entry risks exist for iron dextran?

Generic and follow-on competition can enter through several routes:

• conventional injectable products referencing an approved iron dextran product;
• alternative manufacturers with equivalent active complex specifications;
• hospital-contract products;
• private-label products;
• compounded or outsourced presentations where legally permissible;
• competing intravenous iron complexes with larger doses or simpler administration.

The primary competitive risks are price erosion, formulary substitution, hospital purchasing contracts, and supply reliability. Injectable generics can still face meaningful barriers because sterile manufacturing, container closure qualification, particulate control, and complex characterization increase development costs.

Generic launch scenarios

Scenario	Likely market effect
One additional approved generic	Moderate price pressure; limited clinical switching
Multiple suppliers	Stronger contract competition and lower acquisition cost
Shortage of reference product	Rapid hospital adoption of alternatives
Differentiated ready-to-use product	Premium pricing despite generic competition
Newer high-dose IV iron competitor	Volume loss in infusion centers
Supply disruption affecting competitors	Opportunity for reliable secondary supplier

What commercial opportunities exist for iron dextran?

The most attractive opportunity is not another undifferentiated vial. It is a product that reduces workflow friction or addresses a specific safety and supply problem.

Ready-to-use presentations

Potential products include:

• fixed-dose prefilled syringes;
• small-volume IV bags;
• standardized infusion containers;
• pharmacy-ready unit doses;
• barcoded hospital packaging;
• presentations that reduce bedside dilution or transfer steps.

These products can support premium pricing if they reduce compounding labor, medication errors, wastage, or nursing time.

Lower-volume and faster administration

Iron dextran can be positioned for patients who require substantial iron replacement, but administration time and monitoring requirements affect adoption. A stable formulation with validated low-volume delivery could compete with products that require repeated visits.

Any faster-administration claim would require clinical evidence and careful labeling analysis. It cannot rely solely on excipient selection.

Preservative-free and latex-free packaging

Hospitals increasingly standardize injectable products around preservative-free, latex-free, and low-extractables packaging. These attributes may not create strong patent rights, but they can improve formulary acceptance.

Supply-chain differentiation

A second-source strategy can be valuable because sterile iron products are vulnerable to manufacturing interruptions. Commercial advantages may include:

• dual-source raw materials;
• domestic or regional sterile fill-finish;
• validated alternative container systems;
• reserve capacity;
• long dating period;
• reduced cold-chain dependence;
• transparent elemental-iron assay and impurity specifications.

Global market expansion

Iron-deficiency anemia is prevalent across emerging markets, but the commercial model differs by region. Products must address:

• local registration requirements;
• pharmacopoeial standards;
• import controls;
• hospital procurement;
• vial sizes;
• cold-chain limitations;
• local manufacturing incentives;
• pharmacovigilance obligations.

A stable, low-cost presentation may have more value in price-sensitive markets than a premium device configuration.

How does iron dextran compare with newer intravenous iron products?

Product	Core complex	Typical commercial advantage	Main competitive pressure on iron dextran
Iron dextran	Iron-dextran complex	Established, high iron content, potentially large replacement doses	Hypersensitivity concerns and legacy perception
Iron sucrose	Iron-sucrose complex	Familiar hospital use and established safety profile	May require multiple administrations
Ferric carboxymaltose	Carboxymaltose complex	High-dose administration and broad use	Strong dosing convenience
Ferumoxytol	Carbohydrate-coated iron oxide	High-dose IV use and differentiated pharmacology	Product-specific MRI and hypersensitivity considerations
Ferric derisomaltose	Iron-isomaltoside/derisomaltose complex	Large-dose replacement and simplified schedules	Competes directly on convenience
Sodium ferric gluconate	Ferric gluconate complex	Established dialysis-related use	Lower-dose and repeated-administration profile

Iron dextran's opportunity is strongest where acquisition cost, high elemental-iron delivery, and supply availability outweigh concerns about newer products. Its weakness is the need for careful administration and hypersensitivity management under the product label.[1,3]

Which companies are challenging or competing with iron dextran?

Competition comes from two groups:

1. manufacturers of iron dextran products and generic equivalents;
2. developers and manufacturers of alternative intravenous iron complexes.

American Regent has marketed injectable iron products, including iron dextran-related products in the U.S. market. Covis Pharma and other specialty pharmaceutical companies have been associated with legacy injectable iron brands and rights in various markets. The competitive set also includes major manufacturers of ferric carboxymaltose, ferumoxytol, iron sucrose, ferric derisomaltose, and ferric gluconate.[1,3]

Ownership, marketing rights, and active product status can change by jurisdiction. Product-specific FDA databases and current company labeling should control any transaction or litigation analysis.

What litigation and licensing issues affect iron dextran?

Legacy iron dextran has limited expected exposure to foundational patent litigation because the active product has been marketed for decades. Current disputes are more likely to involve:

• ANDA approval and Paragraph IV certifications;
• manufacturing process patents;
• formulation patents for improved stability;
• trade secrets relating to complex formation;
• supply and distribution agreements;
• trademark ownership;
• product liability;
• adverse-event reporting;
• contract manufacturing failures.

Licensing value would be higher for a differentiated platform than for the legacy active ingredient. Attractive assets may include a ready-to-use presentation, proprietary particle-size control, a validated manufacturing process, a lower-reactivity complex, or a device-enabled administration system.

How strong is the iron dextran patent estate?

The legacy patent estate is weak as a barrier to entry because the product is old and generic competition is possible. A new iron-dextran asset could have a stronger estate if it protects several independent layers:

• composition and excipient system;
• particle-size and free-iron specifications;
• manufacturing sequence;
• container closure;
• ready-to-use dosage form;
• stability profile;
• administration method;
• defined patient population.

The strongest strategy is a layered portfolio with composition, process, and use claims supported by comparative data. Excipient claims without a demonstrated technical effect are less likely to create durable exclusivity.

What is the revenue exposure and launch opportunity?

Iron dextran revenue is exposed to three forces: low-cost generic substitution, migration to newer high-dose iron products, and hospital supply shortages.

A differentiated entrant can improve revenue quality through:

• premium pricing for labor-saving presentations;
• institutional contracts based on supply assurance;
• private-label partnerships;
• regional licensing;
• specialty distribution;
• bundled infusion-center supply;
• contract manufacturing.

The highest-value customer segments are hospitals, dialysis providers, infusion centers, oncology practices, obstetric practices, and health systems managing large injectable-drug formularies.

Key Takeaways

• Iron dextran is an established injectable iron product with expired original exclusivity and substantial generic-entry risk.
• FDA-labeled formulations use a simple excipient system centered on sodium chloride, water for injection, and pH adjustment.[1]
• Excipient innovation must preserve the iron-dextran colloidal complex and avoid increasing free iron, particles, viscosity, oxidation, or hypersensitivity risk.
• The strongest new patent opportunities are likely to involve particle-size control, manufacturing processes, container systems, stability, and administration methods.
• Preservative-free, ready-to-use, low-volume presentations offer the clearest commercial differentiation.
• Manufacturing reliability and sterile supply capacity can be as valuable as formulation novelty.
• Iron dextran competes against ferric carboxymaltose, ferumoxytol, iron sucrose, ferric derisomaltose, and sodium ferric gluconate.
• A new product should be positioned around cost, dose efficiency, workflow reduction, supply security, or a measurable tolerability advantage.

FAQs

Is iron dextran still commercially viable against ferric carboxymaltose?

Yes. Its strongest advantages are established use, high elemental-iron concentration, and potential cost efficiency. Its commercial weakness is the safety and administration profile relative to newer high-dose products.

Can a new excipient create exclusivity for iron dextran?

Yes, but only if the excipient system produces a non-obvious and measurable technical benefit. A routine substitution of sodium chloride, buffer, or tonicity agent is unlikely to provide strong protection by itself.

Is a preservative-free iron dextran product commercially attractive?

Yes. A preservative-free single-dose vial or prefilled syringe can reduce formulation concerns and support hospital formulary adoption, although the presentation must justify its manufacturing and packaging cost.

Can iron dextran be protected with a particle-size patent?

Potentially. A claim directed to a defined particle-size distribution, free-iron level, release profile, and manufacturing process may be stronger than a broad composition claim.

Does iron dextran have biosimilar risk?

No conventional biosimilar pathway applies because iron dextran is not a biological drug in the standard biologics sense. Competition is more likely to arise through generic, follow-on injectable, or alternative complex products, subject to FDA product classification and approval requirements.

References

1. U.S. Food and Drug Administration. (n.d.). INFeD (iron dextran injection) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/